Still another promising approach is a bi-specific antibody (BsAb) with one arm targeting a receptor involved in the receptor-mediated transcytosis pathway of the brain while another one targets the RABV G protein, thus potentially enabling efficient transport of antibody across the BBB, in order to clear RABV from the CNS.